Related Experiment Video

Updated: Sep 25, 2025

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
07:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

2.7K

Antiangiogenic Strategies in Epithelial Ovarian Cancer: Mechanism, Resistance, and Combination Therapy

Chengwen Jin1, Mingyuan Yuan2, Hualei Bu3

  • 1Department of Central Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 Huaihai West Road, Shanghai, China 200030.

Journal of Oncology
|April 25, 2022
PubMed

Insights

Antiangiogenic agents show promise in ovarian cancer treatment but do not increase cures. Combining them with other therapies may overcome resistance and improve outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Angiogenesis is vital for epithelial ovarian cancer progression.
  • Antiangiogenic agents, targeting pathways like VEGF/VEGFR, were the first targeted therapies approved for ovarian cancer.
  • Despite some efficacy, these agents haven't improved cure rates and face challenges like drug resistance and lack of predictive biomarkers.

Purpose of the Study:

  • To review the role and challenges of antiangiogenic agents in epithelial ovarian cancer.
  • To explore potential strategies for overcoming resistance and enhancing treatment efficacy.
  • To highlight the need for predictive biomarkers in antiangiogenic therapy.

Main Methods:

  • Literature review of antiangiogenic agents in ovarian cancer.
  • Analysis of current treatment paradigms and their limitations.
  • Exploration of combination strategies and biomarker development.

Main Results:

  • Antiangiogenic agents, including bevacizumab, offer benefits but do not increase cures in ovarian cancer.
  • Drug resistance and the absence of predictive biomarkers are significant hurdles.
  • Balancing benefits against costs and toxicities is crucial.

Conclusions:

  • Combination therapies with poly (ADP-ribose) polymerase inhibitors or immune checkpoint inhibitors may enhance anti-tumor activity and overcome resistance.
  • Development of predictive biomarkers for antiangiogenic agents is urgently required for personalized treatment strategies.

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.4K
In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer07:46

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer

Published on: August 17, 2010

33.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.0K